Drug releasing systems in cardiovascular tissue engineering

Area of Science:

• Biomedical Engineering
• Cardiovascular Research
• Regenerative Medicine

Background:

• Heart disease and atherosclerosis are leading global causes of death, necessitating improved treatments.
• Current artificial grafts have significant limitations, including thrombosis, infection, and poor durability.
• Tissue engineering offers a promising solution for creating functional cardiovascular replacements.

Purpose of the Study:

• To review advances in drug-delivery systems for tissue-engineered cardiovascular grafts (TECVGs).
• To focus on manufacturing techniques and compounds delivered by these advanced graft systems.
• To explore the potential of TECVGs in cardiovascular repair, drug delivery, and gene therapy.

Main Methods:

• Development of synthetic biodegradable polymer scaffolds seeded with autologous vascular cells.
• Engraftment of scaffolds with growth factors, cytokines, and drugs for localized delivery.
• Review of manufacturing techniques for compound-releasing, tissue-engineered grafts.

Main Results:

• Autologous TECVGs demonstrate potential for growth, durability, and resistance to infection and rejection.
• Drug-releasing systems enable focused and localized delivery of therapeutic molecules.
• TECVGs offer a versatile platform for cardiovascular applications, including drug delivery and gene therapy.

Conclusions:

• TECVGs represent a significant advancement over traditional artificial grafts.
• The integration of drug-delivery systems enhances the therapeutic potential of TECVGs.
• Further development in manufacturing and compound delivery will expand the clinical applications of TECVGs.